Kyowa Pharmaceutical

Kyowa Pharmaceutical Industry Co., Ltd. is a leading Japanese generic pharmaceutical company with a specialized focus on Central Nervous System (CNS) therapeutics, including psychiatry and neurology. Founded in 1954 and headquartered in Osaka, the company markets a broad portfolio of high-quality generic medicines under the "Amel" brand, covering indications such as schizophrenia, depression, and epilepsy. Formerly a subsidiary of Lupin Limited and later owned by Unison Capital, the company was acquired by the private equity firm J-Will Partners in 2024, positioning it as a sister company to Nichi-Iko Pharmaceutical. Kyowa operates major manufacturing facilities in Sanda and Tottori and is actively pursuing a "hybrid" strategy to develop value-added medicines and innovative formulations to improve patient adherence.